Wednesday, October 18, 2017
News

Cipla launches of Hepcvir-L for Chronic Hepatitis C Genotype 1 Patients

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Mumbai | Monday, Dec 21 2015 IST
 
Pharma major, Cipla Ltd, today announced thelaunch of generic drug Ledipasvir-Sofosbuvir in India under thebrand name Hepcvir-L. Hepcvir-L is the first once-a-day, fixed-doseoral combination therapy that has been approved for chronichepatitis C genotype 1 patients.The introduction of the Ledipasvir-Sofosbuvir fixed-dose oralcombination thereby provides a new interferon and ribavirin-freetreatment option to patients and is a powerful weapon to fightagainst genotype 1 hepatitis C virus.Commenting on the launch of Ledipasvir-Sofosbuvir, Mr. SubhanuSaxena, MD & Global CEO, Cipla Limited said, ''Cipla has alwaystried to provide best-in-class affordable medicines to patients andthe launch of Ledipasvir-Sofosbuvir is a further step to facilitatethe optimal treatment for patients suffering from genotype 1hepatitis C virus.''UNI JS NV AW1235

-- (UNI) -- C-1-DL0169-498266.Xml

Watch News Videos

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
Maha Transport Strike: Staff demands imp...
Hyderabad: A self styled god man held fo...
'Guilty must be brought to book': Rahul ...
Adityanath more concerned on celebrating...
Illegal sex-determination: BJP MLAs accu...
Pebble launches 'Dazzle' Bluetooth speak...
More...    
 
 Top Stories
Stock markets to hold Muhurat tradi... 
Previously pregnant donor may up de... 
This sensor 'skin' can help robots ... 
UltraTech Cement's consolidated Q2 ... 
Yuvraj named in domestic violence c... 
Myanmar forces terrorised Rohingyas... 
Deepika draws Irani's attention to ... 
Diwali gift for soldiers: Governmen...